Page | |
3-4 | |
5 | |
6 | |
7-8 | |
9-20 |
| June 30, | December 31, | |||||||
|
2025
|
2024
|
|||||||
|
ASSETS
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
||||
|
Restricted deposits
|
|
|
||||||
|
Short-term bank deposits
|
|
|
||||||
|
Available-for-sale marketable securities
|
|
|
||||||
|
Trade receivables, net (net of allowance for credit losses $
|
|
|
||||||
|
Other receivables and prepaid expenses
|
|
|
||||||
|
Inventories
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
NON-CURRENT ASSETS:
|
||||||||
|
Severance pay fund
|
|
|
||||||
|
Restricted deposit
|
|
|
||||||
|
Available-for-sale marketable securities
|
|
|
||||||
|
Operating lease right-of-use assets
|
|
|
||||||
|
Other assets
|
|
|
||||||
|
Property and equipment, net
|
|
|
||||||
|
Intangible assets, net
|
|
|
||||||
|
Goodwill
|
|
|
||||||
|
Total non-current assets
|
|
|
||||||
|
Total assets
|
$
|
|
$
|
|
||||
| June 30, | December 31, | |||||||
|
2025
|
2024
|
|||||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Trade payables
|
$
|
|
$
|
|
||||
|
Employees and payroll accruals
|
|
|
||||||
|
Deferred revenues
|
|
|
||||||
|
Short-term operating lease liabilities
|
|
|
||||||
|
Other payables and accrued expenses
|
|
|
||||||
|
Total current liabilities
|
|
|
||||||
|
LONG-TERM LIABILITIES:
|
||||||||
|
Deferred revenues
|
|
|
||||||
|
Long-term operating lease liabilities
|
|
|
||||||
|
Accrued severance pay
|
|
|
||||||
|
Convertible debt
|
|
|
||||||
|
Total long-term liabilities
|
|
|
||||||
|
SHAREHOLDERS' EQUITY:
|
||||||||
|
Share capital -
|
||||||||
|
Ordinary shares of NIS
|
|
|
||||||
|
Additional paid-in capital
|
|
|
||||||
|
Treasury share at cost -
|
(
|
)
|
(
|
)
|
||||
|
Accumulated other comprehensive income
|
|
|
||||||
|
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
|
Total shareholders' equity
|
|
|
||||||
|
Total liabilities and shareholders' equity
|
$
|
|
$
|
|
||||
|
Six Months Ended
|
||||||||
|
June 30,
|
||||||||
|
|
2025
|
2024
|
||||||
|
Revenues
|
||||||||
|
Products
|
$
|
|
$
|
|
||||
|
Services
|
|
|
||||||
|
Total revenues
|
|
|
||||||
|
|
||||||||
|
Cost of revenues
|
||||||||
|
Products
|
|
|
||||||
|
Services
|
|
|
||||||
|
Total cost of revenues
|
|
|
||||||
|
Gross profit
|
|
|
||||||
|
|
||||||||
|
Operating expenses:
|
||||||||
|
Research and development costs (net of grant participations of $
|
|
|
||||||
|
Sales and marketing
|
|
|
||||||
|
General and administrative
|
|
|
||||||
|
Total operating expenses
|
|
|
||||||
|
|
||||||||
|
Operating loss
|
(
|
)
|
(
|
)
|
||||
|
Loss from extinguishment
|
(
|
)
|
|
|||||
|
Other income
|
|
|
||||||
|
Financial income, net
|
|
|
||||||
|
|
||||||||
|
Loss before income tax expenses
|
(
|
)
|
(
|
)
|
||||
|
Income tax expenses
|
|
|
||||||
|
|
||||||||
|
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
|
||||||||
| Net loss per share: | ||||||||
|
Basic and diluted
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
|
||||||||
| Weighted average number of shares used in per share computations of net loss: | ||||||||
|
Basic and diluted
|
|
|
||||||
|
|
||||||||
|
Unrealized gain (loss) on available-for-sale marketable securities
|
|
(
|
)
|
|||||
|
Total comprehensive profit (loss) from available-for-sale marketable securities
|
|
(
|
)
|
|||||
|
Unrealized gain (loss) on foreign currency cash flow hedges transactions
|
|
(
|
)
|
|||||
|
Net amount reclassified to earnings from hedging transactions
|
(
|
)
|
(
|
)
|
||||
|
Total comprehensive profit (loss) from hedge transactions
|
|
(
|
)
|
|||||
|
Total other comprehensive profit (loss)
|
|
(
|
)
|
|||||
|
Total comprehensive profit (loss)
|
|
(
|
)
|
|||||
|
Ordinary shares
|
Additional
paid-in capital
|
Treasury share
|
Accumulated other
comprehensive income (loss)
|
Accumulated deficit
|
Total
shareholders' equity
|
|||||||||||||||||||||||
|
Outstanding shares
|
Amount
|
|||||||||||||||||||||||||||
|
Balance as of December 31, 2024
|
|
|
|
(
|
)
|
|
(
|
)
|
|
|||||||||||||||||||
|
Issuance of share capital
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Exercise of share options and restricted share units
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Share-based compensation
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Other comprehensive gain
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Net loss
|
-
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Balance as of June 30, 2025
|
|
|
|
(
|
)
|
|
(
|
)
|
|
|||||||||||||||||||
|
Balance as of December 31, 2023
|
|
|
|
(
|
)
|
|
(
|
)
|
|
|||||||||||||||||||
|
Exercise of share options and restricted share units
|
|
|
(
|
)
|
|
|
|
|
||||||||||||||||||||
|
Share-based compensation
|
-
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Other comprehensive loss
|
-
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||
|
Net loss
|
-
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Balance as of June 30, 2024
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
|
||||||||||||||||||
|
|
Six Months Ended
|
|||||||
|
|
June 30,
|
|||||||
|
|
2025
|
2024
|
||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
(
|
)
|
(
|
)
|
||||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
|
|
||||||
|
Share-based compensation
|
|
|
||||||
|
Capital loss
|
|
|
||||||
|
Loss from extinguishment
|
|
|
||||||
|
Other income
|
(
|
)
|
|
|||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Decrease (Increase) in accrued severance pay, net
|
|
(
|
)
|
|||||
|
Decrease in other assets, other receivables and prepaid expenses
|
|
|
||||||
|
Decrease in accrued interest and amortization of premium on available-for sale marketable securities
|
(
|
)
|
(
|
)
|
||||
|
Decrease in operating leases liability
|
(
|
)
|
(
|
)
|
||||
|
Decrease in operating lease right-of-use asset
|
|
|
||||||
|
Increase in trade receivables
|
(
|
)
|
(
|
)
|
||||
|
Decrease in inventories
|
|
|
||||||
|
Increase (Decrease) in trade payables
|
(
|
)
|
|
|||||
|
Increase (Decrease) in employees and payroll accruals
|
|
(
|
)
|
|||||
|
Increase in deferred revenues
|
|
|
||||||
|
Increase (Decrease) in other payables and accrued expenses
|
|
(
|
)
|
|||||
|
Net cash provided by (used in) operating activities
|
|
(
|
)
|
|||||
|
Cash flows from investing activities:
|
||||||||
|
Decrease in restricted deposit
|
|
|
||||||
|
Investment in short-term bank deposits
|
(
|
)
|
(
|
)
|
||||
|
Withdrawal of short-term bank deposits
|
|
|
||||||
|
Purchase of property and equipment
|
(
|
)
|
(
|
)
|
||||
|
Investment in marketable securitie
|
(
|
)
|
(
|
)
|
||||
|
Proceeds from redemption or sale of marketable securities
|
|
|
||||||
|
Proceeds from sale of patent
|
|
|
||||||
|
Net cash provided by (used in) investing activities
|
(
|
)
|
|
|||||
|
|
Six Months Ended
|
|||||||
|
|
June 30,
|
|||||||
|
|
2025
|
2024
|
||||||
|
Cash flows from financing activities:
|
||||||||
|
Issuance of share capital
|
|
|
||||||
|
Proceeds from exercise of stock options
|
|
|
||||||
|
Redemption of convertible debt
|
(
|
)
|
|
|||||
|
Net cash provided by financing activities
|
|
|
||||||
|
Increase in cash and cash equivalents
|
|
|
||||||
|
Cash, cash equivalents at the beginning of the period
|
|
|
||||||
|
Cash, cash equivalents at the end of the period
|
$
|
|
$
|
|
||||
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
|
NOTE 1: -
|
ORGANIZATION AND DESCRIPTION OF BUSINESS
|
|
NOTE 2: -
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| NOTE 2: - |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| NOTE 3: - |
AVAILABLE-FOR-SALE MARKETABLE SECURITIES
|
|
June 30, 2025
|
December 31, 2024
|
|||||||||||||||||||||||||||||||
|
Amortized cost
|
Gross unrealized gain
|
Gross unrealized
loss
|
Fair
Value
|
Amortized cost
|
Gross
unrealized
gain
|
Gross unrealized
loss
|
Fair
value
|
|||||||||||||||||||||||||
|
Available-for-sale - matures within one year:
|
||||||||||||||||||||||||||||||||
|
US Governmental debentures
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
Corporate debentures
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
|
Available-for-sale - matures after one year through three years:
|
||||||||||||||||||||||||||||||||
|
US Governmental debentures
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
Corporate debentures
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||||||||||
| NOTE 4: - |
FAIR VALUE MEASUREMENTS
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| NOTE 4: - |
FAIR VALUE MEASUREMENTS (Cont.)
|
|
As of June 30, 2025
|
||||||||||||||||
|
Fair value measurements using input type
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Available-for-sale marketable securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Foreign currency derivative contracts
|
|
|
|
|
||||||||||||
|
Liabilities:
|
||||||||||||||||
|
Foreign currency derivative contracts
|
|
(
|
)
|
|
(
|
)
|
||||||||||
|
Total financial net assets
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
As of December 31, 2024
|
||||||||||||||||
|
Fair value measurements using input type
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Available-for-sale marketable securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Foreign currency derivative contracts
|
|
|
|
|
||||||||||||
|
Liabilities:
|
||||||||||||||||
|
Foreign currency derivative contracts
|
|
(
|
)
|
|
(
|
)
|
||||||||||
|
Total financial net assets
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
| NOTE 5: - |
DERIVATIVE INSTRUMENTS
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| NOTE 5: - |
DERIVATIVE INSTRUMENTS (Cont.)
|
|
June 30,
|
December 31,
|
|||||||
|
2025
|
2024
|
|||||||
|
Derivatives Designated as Hedging Instruments
|
||||||||
|
Foreign currency contracts
|
$
|
|
$
|
|
||||
|
Derivatives Not Designated as Hedging Instruments
|
||||||||
|
Foreign currency contracts
|
(
|
)
|
|
|||||
|
Total derivative instruments
|
$
|
|
$
|
|
||||
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
|
NOTE 5: -
|
DERIVATIVE INSTRUMENTS (Cont.)
|
|
Foreign exchange forward and
|
June 30,
|
December 31,
|
||||||||
|
options contracts
|
Balance sheet
|
2025
|
2024
|
|||||||
|
Fair value of foreign exchange non-designated hedge transactions
|
Other receivables and prepaid expenses
|
$
|
|
$
|
|
|||||
|
Fair value of foreign exchange non-designated hedge transactions
|
Other payables and accrued expenses
|
(
|
)
|
|
||||||
|
Total derivatives non-designated as hedging instruments
|
$
|
(
|
)
|
$
|
|
|||||
| NOTE 6: - |
INVENTORIES
|
|
June 30,
|
December 31, | |||||||
|
2025
|
2024
|
|||||||
|
Raw materials
|
$
|
|
$
|
|
||||
|
Finished goods
|
|
|
||||||
|
$
|
|
$
|
|
|||||
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
|
NOTE 7: -
|
PROPERTY AND EQUIPMENT, NET
|
|
June 30,
|
December 31,
|
|||||||
|
2025
|
2024
|
|||||||
|
Cost:
|
||||||||
|
Lab equipment
|
$
|
|
$
|
|
||||
|
Computers and peripheral equipment
|
|
|
||||||
|
Office furniture and equipment
|
|
|
||||||
|
Leasehold improvements
|
|
|
||||||
|
SECaaS equipment
|
|
|
||||||
|
|
|
|||||||
|
Accumulated depreciation:
|
||||||||
|
Lab equipment
|
|
|
||||||
|
Computers and peripheral equipment
|
|
|
||||||
|
Office furniture and equipment
|
|
|
||||||
|
Leasehold improvements
|
|
|
||||||
|
SECaaS equipment
|
|
|
||||||
|
|
|
|||||||
|
Depreciated cost
|
$
|
|
$
|
|
||||
| NOTE 8: - |
INTANGIBLE ASSETS, NET
|
| a. |
The following table shows the Company's intangible assets for the periods presented
|
|
June 30,
|
December 31,
|
|||||||
|
2025
|
2024
|
|||||||
|
Original Cost:
|
||||||||
|
Technology
|
$
|
|
$
|
|
||||
|
Backlog
|
|
|
||||||
|
Customer relationships
|
|
|
||||||
|
Software license
|
|
|
||||||
|
IP R&D
|
|
|
||||||
|
$
|
|
$
|
|
|||||
|
Accumulated amortization:
|
||||||||
|
Technology
|
$
|
|
$
|
|
||||
|
Backlog
|
|
|
||||||
|
Customer relationships
|
|
|
||||||
|
Software license
|
|
|
||||||
|
IP R&D
|
|
|
||||||
|
$
|
|
$
|
|
|||||
|
Amortized cost
|
$
|
|
$
|
|
||||
| b. |
Amortization expense for the six months ended June 30, 2025 and 2024, was $
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
|
NOTE 9: -
|
COMMITMENTS AND CONTINGENT LIABILITIES
|
|
a.
|
Liens and guarantees:
|
|
b.
|
Litigations:
|
| NOTE 10: - |
SHAREHOLDERS' EQUITY
|
| a. |
Company's shares:
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| NOTE 10: - |
SHAREHOLDERS' EQUITY (Cont.)
|
| b. |
Share option plan:
|
|
Option Outstanding
|
||||||||
|
Number
of shares upon exercise
|
Weighted average exercise price
|
|||||||
|
Balance as of December 31, 2024
|
|
$
|
|
|||||
|
Forfeited
|
(
|
)
|
$
|
|
||||
|
Exercised
|
(
|
)
|
$
|
|
||||
|
Balance as of June 30, 2025
|
|
$
|
|
|||||
|
Exercisable at end of year
|
|
$
|
|
|||||
|
RSUs
|
||||||||
|
Number
of shares upon exercise
|
Weighted average share price
|
|||||||
|
Outstanding at beginning of year
|
|
$
|
|
|||||
|
Granted
|
|
$
|
|
|||||
|
Vested
|
(
|
)
|
$
|
|
||||
|
Forfeited
|
(
|
)
|
$
|
|
||||
|
Unvested at end of year
|
|
$
|
|
|||||
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| NOTE 10: - |
SHAREHOLDERS' EQUITY (Cont.)
|
| c. |
Private placements:
|
| NOTE 11: - |
TAXES ON INCOME
|
| NOTE 12: - |
GEOGRAPHIC AND SEGMENT INFORMATION
|
|
Six months ended June 30,
|
||||||||
|
2025
|
2024
|
|||||||
|
Europe
|
$
|
|
$
|
|
||||
|
Asia and Oceania
|
|
|
||||||
|
Americas
|
|
|
||||||
|
Middle East and Africa
|
|
|
||||||
|
$
|
|
$
|
|
|||||
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
| NOTE 12: - |
GEOGRAPHIC AND SEGMENT INFORMATION (Cont.)
|
|
Six months ended June 30,
|
||||||||
|
2025
|
2024
|
|||||||
|
1st Customer
|
|
%
|
|
%
|
||||
|
|
%
|
|
%
|
|||||
|
June 30,
|
December 31,
|
|||||||
|
2025
|
2024
|
|||||||
|
Israel
|
$
|
|
$
|
|
||||
|
Other
|
|
|
||||||
|
$
|
|
$
|
|
|||||
|
NOTE 13: -
|
CONVERTIBLE NOTES
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
|
NOTE 14: -
|
RELATED PARTIES BALANCES AND TRANSACTIONS
|
|
NOTE 15: -
|
SUBSEQUENT EVENT
|